BACKGROUND: The cost-effectiveness of early antiretroviral therapy (ART) in persons infected with human immunodeficiency virus (HIV) in serodiscordant couples is not known. Using a computer simulation of the progression of HIV infection and data from the HIV Prevention Trials Network 052 study, we projected the cost-effectiveness of early ART for such persons. METHODS: For HIV-infected partners in serodiscordant couples in South Africa and India, we compared the early initiation of ART with delayed ART. Five-year and lifetime outcomes included cumulative HIV transmissions, life-years, costs, and cost-effectiveness. We classified early ART as very cost-effective if its incremental cost-effectiveness ratio was less than the annual per capita gross domestic product (GDP; $8,100 in South Africa and $1,500 in India), as cost-effective if the ratio was less than three times the GDP, and as cost-saving if it resulted in a decrease in total costs and an increase in life-years, as compared with delayed ART. RESULTS: In South Africa, early ART prevented opportunistic diseases and was cost-saving over a 5-year period; over a lifetime, it was very cost-effective ($590 per life-year saved). In India, early ART was cost-effective ($1,800 per life-year saved) over a 5-year period and very cost-effective ($530 per life-year saved) over a lifetime. In both countries, early ART prevented HIV transmission over short periods, but longer survival attenuated this effect; the main driver of life-years saved was a clinical benefit for treated patients. Early ART remained very cost-effective over a lifetime under most modeled assumptions in the two countries. CONCLUSIONS: In South Africa, early ART was cost-saving over a 5-year period. In both South Africa and India, early ART was projected to be very cost-effective over a lifetime. With individual, public health, and economic benefits, there is a compelling case for early ART for serodiscordant couples in resource-limited settings. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
BACKGROUND: The cost-effectiveness of early antiretroviral therapy (ART) in persons infected with human immunodeficiency virus (HIV) in serodiscordant couples is not known. Using a computer simulation of the progression of HIV infection and data from the HIV Prevention Trials Network 052 study, we projected the cost-effectiveness of early ART for such persons. METHODS: For HIV-infected partners in serodiscordant couples in South Africa and India, we compared the early initiation of ART with delayed ART. Five-year and lifetime outcomes included cumulative HIV transmissions, life-years, costs, and cost-effectiveness. We classified early ART as very cost-effective if its incremental cost-effectiveness ratio was less than the annual per capita gross domestic product (GDP; $8,100 in South Africa and $1,500 in India), as cost-effective if the ratio was less than three times the GDP, and as cost-saving if it resulted in a decrease in total costs and an increase in life-years, as compared with delayed ART. RESULTS: In South Africa, early ART prevented opportunistic diseases and was cost-saving over a 5-year period; over a lifetime, it was very cost-effective ($590 per life-year saved). In India, early ART was cost-effective ($1,800 per life-year saved) over a 5-year period and very cost-effective ($530 per life-year saved) over a lifetime. In both countries, early ART prevented HIV transmission over short periods, but longer survival attenuated this effect; the main driver of life-years saved was a clinical benefit for treated patients. Early ART remained very cost-effective over a lifetime under most modeled assumptions in the two countries. CONCLUSIONS: In South Africa, early ART was cost-saving over a 5-year period. In both South Africa and India, early ART was projected to be very cost-effective over a lifetime. With individual, public health, and economic benefits, there is a compelling case for early ART for serodiscordant couples in resource-limited settings. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
Authors: R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn Journal: Lancet Date: 2001-04-14 Impact factor: 79.321
Authors: Sue J Goldie; Yazdan Yazdanpanah; Elena Losina; Milton C Weinstein; Xavier Anglaret; Rochelle P Walensky; Heather E Hsu; April Kimmel; Charles Holmes; Jonathan E Kaplan; Kenneth A Freedberg Journal: N Engl J Med Date: 2006-09-14 Impact factor: 91.245
Authors: Zanfina Ademi; Hansoo Kim; Ella Zomer; Christopher M Reid; Bruce Hollingsworth; Danny Liew Journal: Br J Clin Pharmacol Date: 2013-04 Impact factor: 4.335
Authors: A J Cecelia; P Christybai; S Anand; K Jayakumar; T Gurunathan; P Vidya; S Solomon; N Kumarasamy Journal: Natl Med J India Date: 2006 Jan-Feb Impact factor: 0.537
Authors: Yazdan Yazdanpanah; Elena Losina; Xavier Anglaret; Sue J Goldie; Rochelle P Walensky; Milton C Weinstein; Siaka Toure; Heather E Smith; Jonathan E Kaplan; Kenneth A Freedberg Journal: AIDS Date: 2005-08-12 Impact factor: 4.177
Authors: Susan H Eshleman; Sarah E Hudelson; Andrew D Redd; Lei Wang; Rachel Debes; Ying Q Chen; Craig A Martens; Stacy M Ricklefs; Ethan J Selig; Stephen F Porcella; Supriya Munshaw; Stuart C Ray; Estelle Piwowar-Manning; Marybeth McCauley; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Guy de Bruyn; Beatriz Grinsztejn; Nagalingeswaran Kumarasamy; Joseph Makhema; Kenneth H Mayer; Jose Pilotto; Breno R Santos; Thomas C Quinn; Myron S Cohen; James P Hughes Journal: J Infect Dis Date: 2011-10-11 Impact factor: 5.226
Authors: Jean B Nachega; Michael Hislop; Hoang Nguyen; David W Dowdy; Richard E Chaisson; Leon Regensberg; Mark Cotton; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2009-05-01 Impact factor: 3.731
Authors: Mark N Lurie; Brian G Williams; Khangelani Zuma; David Mkaya-Mwamburi; Geoff P Garnett; Michael D Sweat; Joel Gittelsohn; Salim S Abdool Karim Journal: AIDS Date: 2003-10-17 Impact factor: 4.177
Authors: Caitlin M Dugdale; Andrea L Ciaranello; Linda-Gail Bekker; Madeline E Stern; Landon Myer; Robin Wood; Paul E Sax; Elaine J Abrams; Kenneth A Freedberg; Rochelle P Walensky Journal: Ann Intern Med Date: 2019-04-02 Impact factor: 25.391
Authors: Xiao Zang; Emanuel Krebs; Linwei Wang; Brandon D L Marshall; Reuben Granich; Bruce R Schackman; Julio S G Montaner; Bohdan Nosyk Journal: Pharmacoeconomics Date: 2019-10 Impact factor: 4.981
Authors: Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel Journal: Ann Intern Med Date: 2016-05-31 Impact factor: 25.391
Authors: Eleanor J Murray; James M Robins; George R Seage; Sara Lodi; Emily P Hyle; Krishna P Reddy; Kenneth A Freedberg; Miguel A Hernán Journal: Med Decis Making Date: 2017-11-15 Impact factor: 2.583
Authors: Emily P Hyle; Ilesh V Jani; Katherine L Rosettie; Robin Wood; Benjamin Osher; Stephen Resch; Pamela P Pei; Paolo Maggiore; Kenneth A Freedberg; Trevor Peter; Robert A Parker; Rochelle P Walensky Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Dustin J Rabideau; Pamela P Pei; Rochelle P Walensky; Amy Zheng; Robert A Parker Journal: Med Decis Making Date: 2017-11-09 Impact factor: 2.583